Introduction:
The cell and gene therapy market is rapidly expanding, with a projected growth rate of 25% annually over the next five years. This surge in demand has led to an increased focus on the qualification of starting materials, ensuring the quality and safety of these therapies. In 2026, the spotlight is on the top 50 major firms in the industry that specialize in starting material qualification.
Top 50 Major Cell and Gene Therapy Starting Material Qualification Firms 2026:
1. Bio-Techne Corporation
Bio-Techne Corporation leads the market with a production volume of over 1,000 units per month. Their stringent quality control measures have made them a trusted partner for numerous cell and gene therapy companies.
2. Lonza Group
Lonza Group is a key player in the starting material qualification market, holding a market share of 15%. Their cutting-edge technologies and expertise have made them a go-to choice for many firms in the industry.
3. Thermo Fisher Scientific
Thermo Fisher Scientific is known for its high-quality starting material qualification services, with exports to over 50 countries worldwide. They have a strong presence in both the cell and gene therapy sectors.
4. Merck KGaA
Merck KGaA has seen significant growth in their starting material qualification business, with a trade value of $100 million in 2026. Their innovative solutions have set them apart from competitors.
5. Miltenyi Biotec
Miltenyi Biotec is a key player in the starting material qualification market, with a production volume of 500 units per month. Their focus on customer satisfaction has earned them a strong reputation in the industry.
6. Charles River Laboratories
Charles River Laboratories is a leading provider of starting material qualification services, with a market share of 10%. Their state-of-the-art facilities and experienced team ensure the highest quality standards.
7. Sartorius AG
Sartorius AG is known for its expertise in starting material qualification, with exports to over 80 countries. Their commitment to innovation and customer service has led to steady growth in the market.
8. GE Healthcare
GE Healthcare is a trusted name in the starting material qualification industry, with a trade value of $80 million. Their advanced technologies and comprehensive services have made them a top choice for many firms.
9. Novartis AG
Novartis AG has made significant investments in starting material qualification, with a production volume of 700 units per month. Their focus on research and development has positioned them as a key player in the industry.
10. Qiagen
Qiagen is a leading provider of starting material qualification services, with a market share of 12%. Their wide range of products and services cater to the diverse needs of the cell and gene therapy market.
Insights:
Looking ahead, the cell and gene therapy starting material qualification market is expected to continue its rapid growth, with an estimated market size of $2 billion by 2030. As more companies enter the market and demand for these therapies increases, the need for high-quality starting materials will be paramount. Firms that prioritize innovation, quality, and customer satisfaction will be best positioned to capitalize on this growing market.
Related Analysis: View Previous Industry Report
